Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial

The goal of this clinical trial is to test meal-timing as a novel and sustainable interventional approach during cancer treatment to improve therapeutic response and metabolic health in an understudied population. This clinical trial will enroll patients with rectal or breast cancer receiving neoadjuvant treatment at the Alaska Native Medical Center (ANMC), which is part of the Alaska Native Tribal Health Consortium (ANTHC). A promising strategy for improving the efficacy of anticancer treatments and reducing associated toxicities involves combining treatment with fasting regimens. In pre-cli

Trial Details

NCT ID
NCT06802172
Phase
NA
Sponsor
Fred Hutchinson Cancer Center
Status
RECRUITING
Cancer Type
Rectal Cancer Colorectal Cancer
Interventions
  • Time-restricted eating
  • Questionnaire Administration
  • Biospecimen Collection
  • Health coaching
Locations (sample)
  • Anchorage, Alaska, United States|61.21806,-149.90028

Key Eligibility Criteria

  • Male or female
  • Self-identify as Alaska Native or American Indian person and eligible for care at the ANMC
  • Age≥21 years
  • Histologically confirmed rectal cancer stage II, III, or IV (if curative) per AJCC criteria (neoadjuvant)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Rectal Cancer Colorectal Cancer Trials on Trialify →